EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

An Open-label Phase 2 Study of Eneboparatide, a Novel PTH Receptor 1 Agonist, in Hypoparathyroidism

Istvan Takacs iD, Emese Mezosi iD, Alfonso Soto iD, Peter Kamenický iD, Lucile Figueres iD, Maria Angeles Galvez Moreno iD, Sandrine Lemoine iD, Francoise Borson-Chazot iD, Ismael Capel iD, Taha Ouldrouis iD, Nadège Lucas iD, Soraya Allas iD und 3 weitere

The Journal of Clinical Endocrinology & Metabolism · 13.08.2024 · 109 (9) · 2199-2209

DOI: 10.1210/clinem/dgae121 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 06.03.2024. Verfasst von Istvan Takacs und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Oncology, Semmelweis University, 1088 Budapest, Hungary. Hauptthemen laut MEDLINE: Hypoparathyroidism, Receptor, Parathyroid Hormone, Type 1. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Amolyt Pharma, France.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Hypoparathyroidism is a rare disorder characterized by a deficiency in PTH resulting in hypocalcemia, hyperphosphatemia, and hypercalciuria. Eneboparatide is an investigational peptide agonist of the PTH1 receptor for the treatment of chronic hypoparathyroidism (HP).

Objective

To evaluate the efficacy, safety, and tolerability of eneboparatide in HP patients.

Design

Open-label, phase 2 study.

Participants

Twenty-eight patients (21 women, 7 men), mean age (range): 58 years (28-72), with HP were enrolled into 2 consecutive cohorts (C1, n = 12 and C2, n = 16).

Intervention

Following an optimization period, daily subcutaneous injections of eneboparatide were administered for 3 months at a 20 µg/day (C1) or 10 µg/day (C2) starting dose. Conventional therapy was progressively removed, and eneboparatide could be titrated up to 60 µg (C1) or 80 µg (C2). Main outcomes Proportion of patients achieving independence from conventional therapy, albumin-adjusted serum calcium (ADsCa), 24-h urine calcium (uCa), serum bone turnover markers (serum carboxy-terminal telopeptide of type I collagen and procollagen 1 intact N-terminal propeptide), bone mineral density (BMD), and adverse events (AEs).

Results

After 3 months, ≥ 88% of patients achieved independence from conventional therapy while mean ADsCa was maintained within target range (7.8-9 mg/dL). Eneboparatide induced a rapid and sustained reduction of mean 24-hour uCa, even among patients with hypercalciuria. Bone turnover markers slightly increased, and BMD remained unchanged, consistent with progressive resumption of physiologic bone turnover. Eneboparatide was well tolerated with no serious AEs.

Conclusion

Eneboparatide allowed independence from conventional therapy and maintenance of serum calcium within a target range while normalizing uCa excretion and producing a balanced resumption of bone turnover.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypoparathyroidismReceptor, Parathyroid Hormone, Type 1HumansFemaleMiddle AgedMaleAdultAgedBone DensityTreatment OutcomeCalcium

Stichwörter der Autor:innen

bone biomarkerscalciumeneboparatidehypoparathyroidismparathyroid hormonereplacement therapy

Substanzen

Receptor, Parathyroid Hormone, Type 1CalciumPTH1R protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine and Oncology, Semmelweis University, 1088 Budapest, Hungary.
  • Department of Endocrinology, Pecsi Tudomanyegyetem, 7623 Pecs, Hungary.
  • Department of Endocrinology and Nutrition, Complejo Hospitalario Universitario A Coruña, 15006 Coruña, Spain.
  • Physiologie et Physiopathologie Endocriniennes, AP-HP, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphate, Univ…
  • Department of Nephrology and Clinical Immunology, Centre Hospitalier Universitaire Nantes-Université de Nantes, 44093 Nantes, France.
  • Department of Endocrinology and Nutrition, Hospital Universitario Reina Sofía, 14004 Cordoba, Spain.

ORCID-Profile: Istvan Takacs, Emese Mezosi, Alfonso Soto, Peter Kamenický, Lucile Figueres, Maria Angeles Galvez Moreno, Sandrine Lemoine, Francoise Borson-Chazot, Ismael Capel, Taha Ouldrouis, Nadège Lucas, Soraya Allas, Mark Sumeray, Michel Ovize, Michael Mannstadt

Förderung

  • Amolyt Pharma, France

Zitieren

APA

Takacs, I., Mezosi, E., Soto, A., Kamenický, P., Figueres, L., Galvez Moreno, M. A., Lemoine, S., Borson-Chazot, F., Capel, I., Ouldrouis, T., Lucas, N., Allas, S., Sumeray, M., Ovize, M., & Mannstadt, M. (2024). An Open-label Phase 2 Study of Eneboparatide, a Novel PTH Receptor 1 Agonist, in Hypoparathyroidism. The Journal of Clinical Endocrinology & Metabolism, 109(9), 2199-2209. https://doi.org/10.1210/clinem/dgae121

Vancouver

Takacs I, Mezosi E, Soto A, Kamenický P, Figueres L, Galvez Moreno MA, et al. An Open-label Phase 2 Study of Eneboparatide, a Novel PTH Receptor 1 Agonist, in Hypoparathyroidism. The Journal of Clinical Endocrinology & Metabolism. 2024;109(9):2199-2209. doi:10.1210/clinem/dgae121

BibTeX
@article{Takacs2024,
  author = {Takacs, Istvan and Mezosi, Emese and Soto, Alfonso and Kamenický, Peter and Figueres, Lucile and Galvez Moreno, Maria Angeles and Lemoine, Sandrine and Borson-Chazot, Francoise and Capel, Ismael and Ouldrouis, Taha and Lucas, Nadège and Allas, Soraya and Sumeray, Mark and Ovize, Michel and Mannstadt, Michael},
  title = {An Open-label Phase 2 Study of Eneboparatide, a Novel PTH Receptor 1 Agonist, in Hypoparathyroidism},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  volume = {109},
  number = {9},
  pages = {2199--2209},
  doi = {10.1210/clinem/dgae121}
}
Kostenlos starten →